Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide - Lyngbæk, S; Winkel, P; Gøtze, J P (Eur J Prev Cardiol, 2014)
, et al; CLARICOR Trial Group.